Pharma Equity Group A/S Cl A (PEG) - Total Assets

Latest as of December 2025: Dkr38.90 Million DKK ≈ $6.09 Million USD

Based on the latest financial reports, Pharma Equity Group A/S Cl A (PEG) holds total assets worth Dkr38.90 Million DKK (≈ $6.09 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pharma Equity Group A/S Cl A book value and equity for net asset value and shareholders' equity analysis.

Pharma Equity Group A/S Cl A - Total Assets Trend (2008–2025)

This chart illustrates how Pharma Equity Group A/S Cl A's total assets have evolved over time, based on quarterly financial data.

Pharma Equity Group A/S Cl A - Asset Composition Analysis

Current Asset Composition (September 2025)

Pharma Equity Group A/S Cl A's total assets of Dkr38.90 Million consist of 98.4% current assets and 1.6% non-current assets.

Asset Category	Amount (DKK)	% of Total Assets
Cash & Equivalents	Dkr0.00	1.3%
Accounts Receivable	Dkr37.18 Million	95.6%
Inventory	Dkr0.00	0.0%
Property, Plant & Equipment	Dkr0.00	0.0%
Intangible Assets	Dkr0.00	0.0%
Goodwill	Dkr0.00	0.0%

Asset Composition Trend (2008–2025)

This chart illustrates how Pharma Equity Group A/S Cl A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pharma Equity Group A/S Cl A market cap and net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Pharma Equity Group A/S Cl A's current assets represent 98.4% of total assets in 2025, an increase from 81.4% in 2008.
Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, down from 3.4% in 2008.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
Asset Diversification: The largest asset category is accounts receivable at 95.6% of total assets.

Pharma Equity Group A/S Cl A Competitors by Total Assets

Key competitors of Pharma Equity Group A/S Cl A based on total assets are shown below.

Company	Country	Total Assets
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	USA	$107.75 Million
Halozyme Therapeutics Inc NASDAQ:HALO	USA	$2.22 Billion
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	USA	$1.53 Billion
Inner Mongolia Furui Med Sci SHE:300049	China	CN¥3.42 Billion
Bio-Thera Solutions Ltd SHG:688177	China	CN¥2.39 Billion
Wuhan Keqian Biology Co Ltd SHG:688526	China	CN¥4.75 Billion
Gubra A/S CO:GUBRA	Denmark	Dkr1.32 Billion

Pharma Equity Group A/S Cl A - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	4.33	7.57	0.00
Quick Ratio	4.33	7.57	0.00
Cash Ratio	0.00	0.00	0.00
Working Capital	Dkr29.43 Million	Dkr56.70 Million	Dkr-23.22 Million

Pharma Equity Group A/S Cl A - Advanced Valuation Insights

This section examines the relationship between Pharma Equity Group A/S Cl A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.76
Latest Market Cap to Assets Ratio	0.39
Asset Growth Rate (YoY)	-40.7%
Total Assets	Dkr38.90 Million
Market Capitalization	$15.17 Million USD

Valuation Analysis

Below Book Valuation: The market values Pharma Equity Group A/S Cl A's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Pharma Equity Group A/S Cl A's assets decreased by 40.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Pharma Equity Group A/S Cl A (2008–2025)

The table below shows the annual total assets of Pharma Equity Group A/S Cl A from 2008 to 2025.

Year	Total Assets	Change
2025-09-30	Dkr38.90 Million ≈ $6.09 Million	-40.71%
2024-09-30	Dkr65.61 Million ≈ $10.26 Million	-3.15%
2023-09-30	Dkr67.74 Million ≈ $10.60 Million	-4.69%
2022-09-30	Dkr71.07 Million ≈ $11.12 Million	+11.67%
2021-09-30	Dkr63.65 Million ≈ $9.96 Million	+10.53%
2020-09-30	Dkr57.58 Million ≈ $9.01 Million	-28.77%
2019-09-30	Dkr80.84 Million ≈ $12.65 Million	0.00%
2018-09-30	Dkr80.84 Million ≈ $12.65 Million	-6.33%
2017-09-30	Dkr86.30 Million ≈ $13.50 Million	-31.37%
2016-09-30	Dkr125.75 Million ≈ $19.67 Million	-0.40%
2015-09-30	Dkr126.25 Million ≈ $19.75 Million	+1.84%
2014-09-30	Dkr123.97 Million ≈ $19.40 Million	-50.66%
2013-09-30	Dkr251.24 Million ≈ $39.31 Million	-50.14%
2012-09-30	Dkr503.85 Million ≈ $78.83 Million	-0.77%
2011-09-30	Dkr507.76 Million ≈ $79.44 Million	+2.11%
2010-09-30	Dkr497.26 Million ≈ $77.80 Million	+556.84%
2009-09-30	Dkr75.70 Million ≈ $11.84 Million	-71.07%
2008-09-30	Dkr261.67 Million ≈ $40.94 Million	--

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology

Market Cap

$15.17 Million

Dkr96.98 Million DKK

Market Cap Rank

#25958 Global

#118 in Denmark

Share Price

Dkr0.08

Change (1 day)

+1.80%

52-Week Range

Dkr0.07 - Dkr0.15

All Time High

Dkr2.81